Randomized Trial Backs HIF-2a Inhibition in Advanced RCC

(MedPage Today) -- MADRID -- Treatment with the hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan (Welireg) in advanced, heavily pretreated kidney cancer led to superior outcomes when compared with an older kinase inhibitor...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news